Stereotaxis, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Stereotaxis, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every $100 of sales, $46 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $34 tied up three years earlier. More money tied up than 89% of Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 15% in 3 years, but profit fell: $79 less profit per $100 of extra sales. Lower than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-63.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 76% of Healthcare companies in United States.
Cash Locked Ratio
$46For every $100 of sales, $46 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $34 tied up three years earlier.
More money tied up than 89% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
−$79Sales grew 15% in 3 years, but profit fell: $79 less profit per $100 of extra sales.
Lower than 86% of Healthcare companies in United States.
Asset Productivity Ratio
+15% / -2%In 3 years sales changed by +15% while total assets changed by -2%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-21.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 56% of Healthcare companies in United States.
Cash Cushion Ratio
+8%Cash, after subtracting all debt, equals 8% of its market value (net cash).
Lower than 52% of Healthcare companies in United States.
Tangible Assets Ratio
80%Of every $100 the company owns, $80 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 51% of Healthcare companies in United States.
Tangible Net Worth Ratio
46%Of every $100 of net worth, $46 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 55% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Stereotaxis, Inc. made a loss over the last year. Stereotaxis, Inc. owes $0.69 for every $1 it owns. Stereotaxis, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossStereotaxis, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
5.72The share price is 5.72 times Stereotaxis, Inc.'s book value per share, higher than 75% of Healthcare companies in United States.
Market cap
$100 MThe total market value of all of Stereotaxis, Inc.'s shares at today's price (share price × number of shares), smaller than 65% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$17 MWhat Stereotaxis, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.17Net worth divided by the number of shares. The share price of $1.00 is 5.7 times this, which is the P/B above.
Return on equity (ROE)
-184.3%Stereotaxis, Inc. lost 184.3% of its shareholders' money over the last year, lower than 83% of Healthcare companies in United States.
Owes vs Owns
0.69×Stereotaxis, Inc. owes $0.69 for every $1 it owns (moderate), higher than 71% of Healthcare companies in United States.
Dividend yield
NoneStereotaxis, Inc. does not currently pay a dividend.
Revenue growth
+20%Revenue rose 20% in the year to Dec 2025, and grew 5% a year on average over 3 years.
Profit growth
LossStereotaxis, Inc. made a loss in each of the last two years.
Profit margin
-66.8%Stereotaxis, Inc. lost $67 for every $100 of revenue.
Cash vs debt
Net cashStereotaxis, Inc. held $8 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Stereotaxis, Inc.: $100 M ÷ $17 M (30 Jun 2026) = 5.7.
What is Stereotaxis, Inc.'s return on equity?
Stereotaxis, Inc. lost 184.3% of its shareholders' money over the last year, lower than 83% of Healthcare companies in United States.
How much does Stereotaxis, Inc. owe compared with what it owns?
Stereotaxis, Inc. owes $0.69 for every $1 it owns (moderate), higher than 71% of Healthcare companies in United States.
Does Stereotaxis, Inc. pay a dividend?
No. Stereotaxis, Inc. does not currently pay a dividend.
Is Stereotaxis, Inc.'s revenue growing?
Revenue rose 20% in the year to Dec 2025, and grew 5% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.